Latest Conference Articles

Dr Kalinsky on Abemaciclib/Fulvestrant in HR+/HER2– Breast Cancer Post–CDK4/6i Progression

Kevin Kalinsky, MD, MS, on abemaciclib plus fulvestrant in HR-positive/HER2-negative advanced breast cancer after progression on a CDK4/6 inhibitor and endocrine therapy.

Updated CheckMate 816 Data Reinforce Neoadjuvant Nivolumab/Chemo as a SOC for Resectable NSCLC

Neoadjuvant nivolumab with chemotherapy led to durable EFS benefit and a trend toward improved OS vs chemotherapy alone in patients with resectable NSCLC.

DFS, OS Benefit Maintained With Adjuvant Atezolizumab vs BSC in Stage II/IIIA NSCLC

Long-term DFS and OS outcomes with adjuvant atezolizumab in stage II to IIIA NSCLC were consistent with prior data from the IMpower010 trial.

KIM-1 Shows Prognostic and Predictive Value With Adjuvant Atezolizumab in RCC

Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease (MRD), disease recurrence, and benefit from adjuvant atezolizumab (Tecentriq) in patients with renal cell carcinoma (RCC) at increased risk of recurrence.

Lenvatinib/Pembrolizumab Yields Greater Clinical Benefit vs Sunitinib Regardless of Biomarker Subtypes in ccRCC

Lenvatinib plus pembrolizumab displayed a superior clinical benefit vs sunitinib irrespective of patient biomarker subtype in advanced clear cell RCC.

CRS, ICANS Incidence Reduced to Zero Following Tocilizumab, Teclistamab Administration in R/R Multiple Myeloma

Tocilizumab plus teclistamab step-up dosing showed efficacy and a mainly mild safety profile in patients with relapsed/refractory multiple myeloma.

Belantamab Mafodotin Plus BVd Produces PROs Comparable to DVd in Relapsed/Refractory Multiple Myeloma

Treatment with BVd elicited PROs comparable with those who were treated with DVd in relapsed/refractory multiple myeloma.

PRO Data Add to Efficacy and Safety of Frontline Enfortumab Vedotin/Pembrolizumab in Advanced Urothelial Carcinoma

Enfortumab vedotin plus pembrolizumab did not negatively affect quality of life in patients with advanced urothelial carcinoma.

Exploring Newly Released Data in GU and GI Cancers: Drs Grivas and Marshall

Decreased Azacitadine Dosing Shows Consistent Safety in Lower- and Intermediate-Risk MDS

Treatment with a decreased dosing schedule of oral azacitidine was consistent with what has been previously known about the agent in intermediate-risk myelodysplastic syndrome.

Belantamab Mafodotin Significantly Extends PFS vs Daratumumab in Myeloma

Belantamab mafodotin plus bortezomib and dexamethasone improved median progression-free survival vs daratumumab plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

Dr Vogel on Updated OS Data for Frontline Camrelizumab Plus Rivoceranib in Unresectable HCC

Arndt Vogel, MD, on the final overall survival data for camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma.

Dr Ramalingam on Osimertinib Post-Chemoradiotherapy in Unresectable, Stage III, EGFR-Mutated NSCLC

Suresh S. Ramalingam, MD, FACP, FASCO, discusses findings with osimertinib after definitive chemoradiotherapy in unresectable EGFR-mutated NSCLC.

First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC

Rivoceranib plus camrelizumab maintained a survival benefit vs sorafenib in advanced, unresectable hepatocellular carcinoma.

Addition of Atezolizumab to Chemotherapy and Bevacizumab Does Not Yield Benefit in Ovarian Cancer

The addition of atezolizumab to bevacizumab and chemotherapy did not significantly improve overall survival or progression-free survival in patients with recurrent ovarian cancer.

Liver Transplantation Plus Chemotherapy Improves 5-Year OS Rate in Patients With CRC Liver Metastases

Integrating liver transplantation into treatment with chemotherapy improved survival at 5 years vs chemotherapy alone in patients with definitively unresectable CRC liver metastases.

mIF Biomarker Not Associated With Improved Outcomes With Nivolumab/Ipilimumab Treatment in Metastatic Clear Cell RCC

Using CD8-positive, PD-1-positive, TIM3-negative, and LAG3-negative TILs as a biomarker was not associated with improved clinical outcomes for patients with mccRCC treated with nivolumab plus ipilimumab.

Taletrectinib Yields Durable Responses in TKI Naive and Crizotinib Pretreated ROS1+ NSCLC

Taletrectinib demonstrated high response rates and a tolerable safety profile in patients with ROS1-positive non–small cell lung cancer.

Nivolumab/Ipilimumab Bests Nivolumab in Ovarian and Extra-Renal Clear Cell Carcinomas

The combination of nivolumab and ipilimumab improved responses as well as survival outcomes in patients with ovarian or gynecologic clear cell carcinomas.

Trastuzumab Deruxtecan Prolongs PFS in Pretreated HR+, HER2-Low and -Ultralow Metastatic Breast Cancer

Trastuzumab deruxtecan improved PFS vs chemotherapy in pretreated, HR-positive, HER2-low or -ultralow metastatic breast cancer.

Zanidatamab Shows Durable Responses With Longer Follow-up in Pretreated HER2+ Biliary Tract Cancer

Zanidatamab continued to show confirmed responses, disease control, and prolonged overall survival in pretreated HER2+ biliary tract cancer.

Cabazitaxel/Abiraterone Combination Prolongs PFS vs Abiraterone in mCRPC

Cabazitaxel plus abiraterone acetate and prednisone improved PSA response and extended PFS vs abiraterone acetate and prednisone in patients with mCRPC.

Pembrolizumab Plus Sacituzumab Govitecan Shows Nonsignificant Trend Toward Improved PFS in HR+ Breast Cancer

Pembrolizumab plus sacituzumab govitecan numerically improved PFS vs the ADC alone in HR-positive, HER2-negative metastatic breast cancer.

Virtual and In-Person Delivery of Palliative Care Confers Equivalent QOL Benefit in Advanced Lung Cancer

The delivery of palliative care through telehealth vs in-person visits was equally beneficial for patients with advanced non–small cell lung cancer.

Lymphadenectomy Fails to Boost Survival in Advanced Ovarian Cancer

The addition of lymphadenectomy to cytoreductive surgery did not improve progression-free or overall survival in advanced ovarian cancer.

Consolidation Durvalumab to Become New SOC for LS-SCLC After Chemoradiation

Consolidation treatment with durvalumab after concurrent chemoradiation led to a survival benefit vs placebo in limited-stage small cell lung cancer.

Osimertinib Could Alter SOC for Stage III EGFR+ NSCLC

Osimertinib after definitive chemoradiotherapy improved PFS vs placebo in locally advanced, EGFR-mutated non–small cell lung cancer.

Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer

Perioperative chemotherapy with FLOT improved OS vs neoadjuvant chemoradiation with CROSS in resectable esophageal cancer.

Neoadjuvant Nivolumab/Ipilimumab New Standard of Care for Stage III Melanoma

Neoadjuvant nivolumab/ipilimumab followed by TLND and response-driven adjuvant therapy reduced the risk of progression, recurrence, or death in melanoma.

Belantamab Mafodotin Plus Pd Elicits PFS Benefit in R/R Myeloma

Belantamab mafodotin plus BPd improved PFS vs PVd in relapsed/refractory multiple myeloma.